Express News | NKGen Biotech To Present Updated Phase 1 Data Of SNK02 Allogeneic NK Cell Therapy In Solid Tumors At 6th Annual Allogeneic Cell Therapies Summit 2024

Benzinga08:26 ET

Express News | NKGen Biotech to Present Updated Phase 1 Data on Snk02 Allogeneic Nk Cell Therapy in Solid Tumors at the 6TH Annual Allogeneic Cell Therapies Summit 2024

Reuters08:05 ET

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech, Inc. (Nasdaq: NKGN) today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

GlobeNewswireMay 23 17:05 ET

10-Q: Quarterly report

SEC announcementMay 20 17:02 ET · Announcements

Top Midday Gainers

MultiMetaVerse Holdings (MMV) said Monday that it signed a non-binding term sheet to acquire 100% of Bowong Technology and its subsidiaries for an undisclosed amount. Shares surged 135% as intraday tr

MT NewswiresMay 20 14:00 ET

Trending Stocks Today: MultiMetaVerse Shoots up 136.96%

May 20th - US stocks trending in regular trading hours.Gainers: $MultiMetaVerse(MMV.US)$ shoots up 136.96% to $1.4 with a turnover of $192.18 million. $GT Biopharma(GTBP.US)$ surges 150.32% to $7.81 w

moomoo NewsMay 20 14:00 ET